Article Information
History
- November 3, 2021.
Article Versions
- You are currently viewing Version 1 of this article (November 3, 2021 - 17:31).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Mohammad Talaei1,*,
- Sian Faustini2,*,
- Hayley Holt1,3,4,*,
- David A. Jolliffe1,3,
- Giulia Vivaldi1,3,
- Matthew Greenig1,
- Natalia Perdek1,
- Sheena Maltby1,
- Jane Symons5,
- Gwyneth A Davies6,
- Ronan A Lyons6,
- Christopher J Griffiths1,
- Frank Kee7,
- Aziz Sheikh8,
- Alex G Richter2,
- Seif O Shaheen1 and
- Adrian R Martineau1,3,4,†
- 1Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
- 2Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
- 3Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
- 4Asthma UK Centre for Applied Research, Queen Mary University of London, London, UK
- 5Jane Symons Media, London, UK
- 6Population Data Science, Swansea University Medical School, Singleton Park, Swansea, UK
- 7Centre for Public Health Research (NI), Queen’s University Belfast, Belfast, UK
- 8Usher Institute, University of Edinburgh, Edinburgh, UK
- ↵†Corresponding author: Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, London E1 2AT, UK, Tel: +44 207 882 2551 │Fax: +44 207 882 2552 │Email: a.martineau{at}qmul.ac.uk
↵* Contributed equally.
Posted November 03, 2021.
Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)
